Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. announced positive Phase 2 data for nebokitug in primary sclerosing cholangitis (PSC), to be presented at the AASLD The Liver Meeting® 2025 on November 10, 2025. The data includes results from the trial’s open label extension, highlighting nebokitug’s favorable safety profile and improvements in inflammatory and fibrotic biomarkers over 48 weeks. The presentations are designated as Posters of Distinction, providing insights into nebokitug’s macrophage-mediated mechanisms in PSC.
Chemomab Therapeutics Ltd. announced that new clinical data from the Phase 2 SPRING trial of nebokitug in primary sclerosing cholangitis (PSC) will be presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 on November 10, 2025. The presentations will include results from the trial’s open label extension, demonstrating nebokitug’s favorable safety profile and consistent improvements in key inflammatory and fibrotic biomarkers over up to 48 weeks of treatment. Additional data will provide insights into nebokitug’s macrophage-mediated mechanisms of action in PSC. All three presentations have been designated as Posters of Distinction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570291-en) on November 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
